Atlas Trials

Modulation of the Gut Microbiome With Pembrolizumab Following Chemotherapy in Resectable Pancreatic Cancer

Clinical trial NCT05462496 · RECRUITING

Trial details

NCT number
NCT05462496
Sponsor
Icahn School of Medicine at Mount Sinai
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Pancreatic Cancer
Start date
2023-03-16
Primary completion
2027-08-01
Enrollment
25

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.